MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis.


Journal

Nature cancer
ISSN: 2662-1347
Titre abrégé: Nat Cancer
Pays: England
ID NLM: 101761119

Informations de publication

Date de publication:
04 2022
Historique:
received: 13 08 2021
accepted: 28 02 2022
entrez: 28 4 2022
pubmed: 29 4 2022
medline: 3 5 2022
Statut: ppublish

Résumé

Aberrant expression of MYC transcription factor family members predicts poor clinical outcome in many human cancers. Oncogenic MYC profoundly alters metabolism and mediates an antioxidant response to maintain redox balance. Here we show that MYCN induces massive lipid peroxidation on depletion of cysteine, the rate-limiting amino acid for glutathione (GSH) biosynthesis, and sensitizes cells to ferroptosis, an oxidative, non-apoptotic and iron-dependent type of cell death. The high cysteine demand of MYCN-amplified childhood neuroblastoma is met by uptake and transsulfuration. When uptake is limited, cysteine usage for protein synthesis is maintained at the expense of GSH triggering ferroptosis and potentially contributing to spontaneous tumor regression in low-risk neuroblastomas. Pharmacological inhibition of both cystine uptake and transsulfuration combined with GPX4 inactivation resulted in tumor remission in an orthotopic MYCN-amplified neuroblastoma model. These findings provide a proof of concept of combining multiple ferroptosis targets as a promising therapeutic strategy for aggressive MYCN-amplified tumors.

Identifiants

pubmed: 35484422
doi: 10.1038/s43018-022-00355-4
pii: 10.1038/s43018-022-00355-4
pmc: PMC9050595
doi:

Substances chimiques

MYCN protein, human 0
N-Myc Proto-Oncogene Protein 0
Glutathione GAN16C9B8O
Cysteine K848JZ4886

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

471-485

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2022. The Author(s).

Références

Cell Chem Biol. 2020 Apr 16;27(4):365-375
pubmed: 32294465
Cell Death Differ. 2016 Feb;23(2):270-8
pubmed: 26184909
Nat Chem Biol. 2016 Feb;12(2):109-16
pubmed: 26656090
Proc Natl Acad Sci U S A. 2013 Jun 18;110(25):10258-63
pubmed: 23733953
Cell. 2012 Sep 28;151(1):56-67
pubmed: 23021215
Nat Methods. 2015 Oct;12(10):963-965
pubmed: 26280331
Proc Natl Acad Sci U S A. 2012 Jan 24;109(4):1092-7
pubmed: 22228304
Nucleic Acids Res. 2014 Jul;42(Web Server issue):W187-91
pubmed: 24799436
Nature. 2015 Oct 29;526(7575):700-4
pubmed: 26466568
Cancer Cell. 2012 Nov 13;22(5):631-44
pubmed: 23153536
Genome Biol. 2015 Jun 25;16:133
pubmed: 26109056
F1000Res. 2016 Jun 15;5:1384
pubmed: 30101006
FEBS J. 2022 Jan;289(2):374-385
pubmed: 33773039
Cell Metab. 2019 Nov 5;30(5):865-876.e5
pubmed: 31607565
Mol Cell Biol. 2006 Mar;26(6):2373-86
pubmed: 16508012
Cancer Res. 2016 Sep 15;76(18):5523-37
pubmed: 27635046
Commun Biol. 2018 Nov 28;1:210
pubmed: 30511023
Cell Death Differ. 2011 Jun;18(6):974-84
pubmed: 21233845
Nature. 2020 Sep;585(7823):113-118
pubmed: 32814895
Nat Protoc. 2013 Mar;8(3):539-54
pubmed: 23429716
Nat Genet. 2017 Aug;49(8):1261-1266
pubmed: 28650485
Cancer Discov. 2015 Oct;5(10):1024-39
pubmed: 26382145
Cell Metab. 2020 Dec 1;32(6):920-937
pubmed: 33217331
Genome Biol. 2008 Oct 13;9(10):R150
pubmed: 18851746
Mol Microbiol. 2015 Jun;96(6):1272-82
pubmed: 25807888
Cancer Cell. 2008 Dec 9;14(6):447-57
pubmed: 19061836
Clin Chem. 1997 Dec;43(12):2397-402
pubmed: 9439460
Oncogene. 1996 Aug 15;13(4):803-12
pubmed: 8761302
Cell Syst. 2017 Sep 27;5(3):237-250.e8
pubmed: 28843484
Nucleic Acids Res. 2009 Oct;37(18):e119
pubmed: 19589807
Cell. 2014 Jan 16;156(1-2):317-331
pubmed: 24439385
J Biol Chem. 2015 Jun 19;290(25):15878-15891
pubmed: 25931127
Nat Rev Mol Cell Biol. 2021 Apr;22(4):266-282
pubmed: 33495651
Nat Commun. 2021 Feb 24;12(1):1269
pubmed: 33627664
Mol Cell. 2015 Jul 16;59(2):298-308
pubmed: 26166707
Cancer Res. 2021 Apr 1;81(7):1896-1908
pubmed: 33483374
Cell Chem Biol. 2019 May 16;26(5):623-633.e9
pubmed: 30799221
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18782-7
pubmed: 19033189
Elife. 2014 May 20;3:e02523
pubmed: 24844246
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Front Oncol. 2020 May 07;10:723
pubmed: 32457843
Cancer Res. 2010 May 1;70(9):3791-802
pubmed: 20424123
Cancer Lett. 2005 Oct 18;228(1-2):133-41
pubmed: 15927359
Cell Rep. 2020 Mar 10;30(10):3411-3423.e7
pubmed: 32160546
Cell. 2017 Jul 27;170(3):577-592.e10
pubmed: 28753431
Nat Cancer. 2021 Jan;2(1):114-128
pubmed: 35121888
Mol Cell. 2019 Jan 17;73(2):354-363.e3
pubmed: 30581146
Amino Acids. 2012 Jan;42(1):199-205
pubmed: 21369939
Cell Death Dis. 2021 May 19;12(6):511
pubmed: 34011924
J Exp Bot. 2004 Aug;55(404):1785-98
pubmed: 15258168
Nat Protoc. 2006;1(3):1112-6
pubmed: 17406391
Free Radic Biol Med. 2012 Jul 15;53(2):366-74
pubmed: 22579918
Cell. 2012 May 25;149(5):1060-72
pubmed: 22632970
Adv Exp Med Biol. 2021;1301:1-5
pubmed: 34370284
N Engl J Med. 2010 Jun 10;362(23):2202-11
pubmed: 20558371
In Vivo. 2002 Mar-Apr;16(2):77-85
pubmed: 12073775

Auteurs

Hamed Alborzinia (H)

Heidelberg Institute for Stem Cell Technology and Experimental Medicine, Heidelberg, Germany. hamed.alborzy@gmail.com.
Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, Heidelberg, Germany. hamed.alborzy@gmail.com.
Division of Stem Cells and Cancer German Cancer Research Center and Center for Molecular Biology of the University of Heidelberg Alliance, Heidelberg, Germany. hamed.alborzy@gmail.com.

Andrés F Flórez (AF)

Division of Theoretical Systems Biology, German Cancer Research Center, Heidelberg, Germany.
Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA, USA.

Sina Kreth (S)

Hopp Children's Cancer Center, Heidelberg, Germany.
Division of Neuroblastoma Genomics, German Cancer Research Center, Heidelberg, Germany.

Lena M Brückner (LM)

Hopp Children's Cancer Center, Heidelberg, Germany.
Division of Neuroblastoma Genomics, German Cancer Research Center, Heidelberg, Germany.

Umut Yildiz (U)

Heidelberg Institute for Stem Cell Technology and Experimental Medicine, Heidelberg, Germany.
Division of Stem Cells and Cancer German Cancer Research Center and Center for Molecular Biology of the University of Heidelberg Alliance, Heidelberg, Germany.

Moritz Gartlgruber (M)

Hopp Children's Cancer Center, Heidelberg, Germany.
Division of Neuroblastoma Genomics, German Cancer Research Center, Heidelberg, Germany.

Dorett I Odoni (DI)

Bioinformatics and Omics Data Analytics, German Cancer Research Center, Heidelberg, Germany.
Biomedical Informatics, Data Mining and Data Analytics, Augsburg University, Augsburg, Germany.

Gernot Poschet (G)

Metabolomics Core Technology Platform, University of Heidelberg, Heidelberg, Germany.

Karolina Garbowicz (K)

Hopp Children's Cancer Center, Heidelberg, Germany.
Division of Neuroblastoma Genomics, German Cancer Research Center, Heidelberg, Germany.

Chunxuan Shao (C)

Division of Theoretical Systems Biology, German Cancer Research Center, Heidelberg, Germany.

Corinna Klein (C)

Heidelberg Institute for Stem Cell Technology and Experimental Medicine, Heidelberg, Germany.
Division of Stem Cells and Cancer German Cancer Research Center and Center for Molecular Biology of the University of Heidelberg Alliance, Heidelberg, Germany.

Jasmin Meier (J)

Heidelberg Institute for Stem Cell Technology and Experimental Medicine, Heidelberg, Germany.
Division of Stem Cells and Cancer German Cancer Research Center and Center for Molecular Biology of the University of Heidelberg Alliance, Heidelberg, Germany.

Petra Zeisberger (P)

Heidelberg Institute for Stem Cell Technology and Experimental Medicine, Heidelberg, Germany.
Division of Stem Cells and Cancer German Cancer Research Center and Center for Molecular Biology of the University of Heidelberg Alliance, Heidelberg, Germany.

Michal Nadler-Holly (M)

Proteome Dynamics, Max Delbrück Center for Molecular Medicine, Berlin, Germany.

Matthias Ziehm (M)

Proteome Dynamics, Max Delbrück Center for Molecular Medicine, Berlin, Germany.

Franziska Paul (F)

Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.

Jürgen Burhenne (J)

Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, Germany.

Emma Bell (E)

Hopp Children's Cancer Center, Heidelberg, Germany.
Division of Neuroblastoma Genomics, German Cancer Research Center, Heidelberg, Germany.

Marjan Shaikhkarami (M)

Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, Heidelberg, Germany.

Roberto Würth (R)

Heidelberg Institute for Stem Cell Technology and Experimental Medicine, Heidelberg, Germany.
Division of Stem Cells and Cancer German Cancer Research Center and Center for Molecular Biology of the University of Heidelberg Alliance, Heidelberg, Germany.

Sabine A Stainczyk (SA)

Hopp Children's Cancer Center, Heidelberg, Germany.
Division of Neuroblastoma Genomics, German Cancer Research Center, Heidelberg, Germany.

Elisa M Wecht (EM)

Hopp Children's Cancer Center, Heidelberg, Germany.
Division of Neuroblastoma Genomics, German Cancer Research Center, Heidelberg, Germany.

Jochen Kreth (J)

Hopp Children's Cancer Center, Heidelberg, Germany.
Division of Neuroblastoma Genomics, German Cancer Research Center, Heidelberg, Germany.

Michael Büttner (M)

Metabolomics Core Technology Platform, University of Heidelberg, Heidelberg, Germany.

Naveed Ishaque (N)

Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Digital Health Center, Berlin, Germany.

Matthias Schlesner (M)

Bioinformatics and Omics Data Analytics, German Cancer Research Center, Heidelberg, Germany.
Biomedical Informatics, Data Mining and Data Analytics, Augsburg University, Augsburg, Germany.

Barbara Nicke (B)

Target Discovery Technologies, Bayer AG, Berlin, Germany.

Carlo Stresemann (C)

Research & Development, Pharmaceuticals Division, Bayer AG, Berlin, Germany.

María Llamazares-Prada (M)

Division of Cancer Epigenomics, German Cancer Research Center, Member of the German Center for Lung Research, Heidelberg, Germany.

Jan H Reiling (JH)

Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Matthias Fischer (M)

Experimental Pediatric Oncology, Children's Hospital and Center for Molecular Medicine, Medical Faculty, University of Cologne, Cologne, Germany.

Ido Amit (I)

Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.

Matthias Selbach (M)

Proteome Dynamics, Max Delbrück Center for Molecular Medicine, Berlin, Germany.
Charité-Universitätsmedizin Berlin, Berlin, Germany.

Carl Herrmann (C)

Bioinformatics and Omics Data Analytics, German Cancer Research Center, Heidelberg, Germany.
Health Data Science Unit, Medical Faculty University Heidelberg and BioQuant, Heidelberg, Germany.

Stefan Wölfl (S)

Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, Heidelberg, Germany.

Kai-Oliver Henrich (KO)

Hopp Children's Cancer Center, Heidelberg, Germany.
Division of Neuroblastoma Genomics, German Cancer Research Center, Heidelberg, Germany.

Thomas Höfer (T)

Division of Theoretical Systems Biology, German Cancer Research Center, Heidelberg, Germany.

Andreas Trumpp (A)

Heidelberg Institute for Stem Cell Technology and Experimental Medicine, Heidelberg, Germany.
Division of Stem Cells and Cancer German Cancer Research Center and Center for Molecular Biology of the University of Heidelberg Alliance, Heidelberg, Germany.
German Cancer Consortium, Heidelberg, Germany.

Frank Westermann (F)

Hopp Children's Cancer Center, Heidelberg, Germany. f.westermann@dkfz.de.
Division of Neuroblastoma Genomics, German Cancer Research Center, Heidelberg, Germany. f.westermann@dkfz.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH